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Abstract
Background: Diabetic nephropathy has a high cardiovascular risk with a low-level HDL(high density lipoprotein) in
epidemiologic studies. Glycated HDL in diabetes can diminish the capacity to stimulate endothelial cell migration,
but the mechanism has not been adequately explored in diabetic nephropathy. We performed this study to find
out whether HDL in diabetic nephropathy is more dysfunctional than HDL in diabetes without complications.
Methods: Endothelial cells were treated with N-HDL (normal), D-HDL (T2DM[type 2 diabetes mellitus] without
complications), DN-HDL (T2DM nephropathy), N-apoA-I (normal apoA-I), and G-apoA-I (glycated apoA-I in vitro).
Cell migration capacity was measured with wound-healing and transwell migration assay in vitro and electric
carotid injury model in vivo. Protein glycation levels were measured with nanoLC-MS/MS. PI3K expression and
Akt phosphorylation were analyzed by western blot.
Results: In wound-healing assay, DN-HDL showed a 17.12 % decrease compared with D-HDL (p < 0.05). DN-HDL
showed a 29.85 % decrease in comparison with D-HDL (p < 0.001) in transwell assay. In the electric carotid injury
model, D-HDL and DN-HDL impaired the re-endothelialization capacity; DN-HDL was less effective than D-HDL.
Meanwhile, DN-HDL was found to have a significantly higher protein glycation level than D-HDL (p < 0.001). PI3K
expression and Akt phosphorylation were reduced significantly in DN-HDL in comparison with D-HDL and N-HDL.
Conclusions: We found that HDL from diabetic nephropathy has a higher level of glycation and induced less cell
migration in vitro and in vivo compared with that from diabetes without nephropathy. This finding suggests that
diabetic nephropathy has higher levels of glycated HDL and partially explains why patients with DN have a higher
risk of cardiovascular disease.
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Background
Type 2 diabetes mellitus (T2DM) and chronic kidney
disease (CKD) are two major growing public health
problems all over the world [1, 2]. Cardiovascular dis-
ease is the leading cause of morbidity and mortality of
diabetes, accounting for up to 80 % of premature
mortality in diabetes patients [3, 4]. Many epidemio-
logical and clinical trials have demonstrated that
diabetes is the major cause of CKD with the risk of
developing CVD(cardiovascular disease) when CKD
and diabetes coexist [1, 5, 6]. However, why there is
higher cardiovascular risk when diabetes coexists with
CKD is not clear [3].
Epidemiological studies have provided overwhelming
evidence that arteriosclerosis is core to the pathological
process of cardiovascular diseases with dyslipidemia
being an important risk factor for atherosclerosis in dia-
betes [7, 8]. High levels of LDL(low density lipoprotein)
and low levels of HDL are typical features of
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dyslipidemia and both have been shown to be independ-
ent predictors of CVD in diabetes [9–14]. Additionally, a
prospective study showed that low baseline HDL
levels are a significant and independent predictor of
the development and progression of diabetic nephrop-
athy (DN) [15].
The main component of HDL is apolipoprotein A-I
(apoA-I) [16, 17]. HDL can enhance endothelial progeni-
tor cell endothelium repair and stimulate endothelia cell
proliferation and migration by activating endothelial ni-
tric oxide synthase [18, 19]. Endothelial damage is crit-
ical in the development of CVD, and endothelial cell
migration is a rate-limiting process in the repair of
endothelium [7]. HDL in diabetes is dysfunctional in
stimulating endothelial cell migration and proliferation
with glycation of HDL, one of contributors to its dys-
function [20, 21]. Dysfunctional HDL could be an
important factor in the development of diabetic cardio-
vascular disease [16]. The relationship between HDL in
DN and CVD has not been sufficiently explored and
specifically whether there is a difference in HDL glyca-
tion between patients with DN and diabetes without
complications. It has been demonstrated that HDL can
interact with SR-BI and activate the small G protein Rac
via Src kinase, phosphoinositol 3-kinase (PI3K), Akt, and
ERK, which stimulate the rapid initial lamellipodia for-
mation, an indicator of cell migration [7].
We hypothesized that the function of HDL is more
compromised in DN patients than in diabetic patients
without complications due to glycation, and that dys-
functional HDL leads to severely reduced capacity to
stimulate endothelial cell migration. Using wound-
healing assay, transwell migration assay in vitro, and
electric injury model in vivo we investigated whether N-
HDL (normal), D-HDL (T2DM without complications),
and DN-HDL (T2DM nephropathy) have significantly
different functions in stimulating EC migration. We ex-
plored the relationship between HDL glycation levels
through mass spectrometry and the capacity to stimulate
human umbilical vein endothelial cell (HUVEC) migra-
tion. We also attempted to find out whether these differ-
ences involved the PI3K/Akt pathways.
We found that HDL from DN has a higher level of
glycation and induced less cell migration capacity com-
pared with diabetes without complications. The mechan-
ism of endothelial cell migration reduction partially




Healthy volunteers (n = 12) and patients with type 2 dia-
betes mellitus without complications (n = 18) and pa-
tients with diabetic nephropathy without CVD (n = 18)
were recruited from Capital Medical University Pinggu
Teaching Hospital. Written informed consent was ob-
tained from every participant before the study began,
and the hospital’s ethics committee approved the proto-
col for data collecting involving human subjects for this
study. Each volunteer went through a medical-history
check, a physical examination, a 75 g oral glucose toler-
ance test, and other laboratory screening tests. Type 2
diabetes and diabetic nephropathy patients were all diag-
nosed by physicians. Type 2 diabetes patients without
complications, which include nephropathy, retinopathy,
CVD, and other vascular diseases, were enrolled. Dia-
betic nephropathy was defined as diabetes with the con-
sistent presence of albuminuria (the ratio between urine
albumin and the creatinine was 30 mg/g or higher [22])
or impaired GFR(glomerular filtration rate) or both. In
addition, all participants in this group must have been
diagnosed with diabetic retinopathy. About two-third
(11 in total) diabetic and equivalent (12 in total) dia-
betic nephropathic patients were on antihypertensive,
hypoglycemic and lipid-lowering medications. Clinical
and laboratory characteristics of the study participants
are shown in the Table 1.
Animals
Six to eight-week-old male ICR mice were obtained from
the Department of Laboratory Animal Science, Peking
University, and the Ethics Committee of Animal Research,
Peking University Health Science Center approved all ani-
mal experimental procedures.
Cell culture
HUVECs were isolated by collagenase digestion of um-
bilical veins from fresh cords and cultured with endothe-
lial cell medium containing 5 % bovine serum, 1 %
endothelial cell growth supplement, and 1 % penicillin/
streptomycin solution, in a humidified atmosphere (5 %
CO2) at 37 °C. HUVECs used in all experiments were at
passages 3–5. Cells were starved overnight for further
treatment.
Isolation of high-density lipoprotein
Fasting peripheral blood was collected in vacuum blood
tube containing EDTA from healthy (N), diabetic (D)
and diabetic nephropathy (DN) subjects. LDL (1.019–
1.063 g/ml) and HDL (1.063–1.210 g/ml) were isolated
from fresh plasma by ultracentrifugation after the
plasma from 18 individuals was mixed as a pool [23].
The plasma was centrifuged at 550,000 g for 5 h at 4 °C.
HDL was dialyzed against endotoxin-free phosphate-
buffered saline (10 mM, PH7.4) for 3 days in the dark at
4 °C. The purity of HDL was confirmed by the 12 % so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). The concentration of HDL was measured
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by nephelometry (Dimension XPand, Dade Behring,
Germany). HDL was sterilized through the 0.22 um filter
and then stored in sealed tubes at 4 °C in the dark, ready
to be used within 1 month.
Endothelial cell migration assays
Wound-healing migration assay
Cell migration capacity can be reflected through wound-
healing migration assay [24]. In this experiment,
HUVECs were planted in 6-well plates with 1.2 ml endo-
thelial cell medium containing 5 % bovine serum and
cultured until monolayers were formed. Then HUVECs
were scratched with a 200 ul micropipette tip, and cells
were incubated with endothelial cell medium containing
1 % bovine serum respectively with PBS, N-HDL, D-
HDL, or DN-HDL with an apoA-I concentration of
100 μg/ml for 10 h. Cells were photographed with an
inverted microscope (Nikon, Japan), and cell migration
was quantified using the migrated gap distance in six
random high-power (50X) fields.
Transwell migration assay
Apart from wound-healing migration assay, quantitative
cell migration assay was performed with a modified
Boyden chamber (Minicell, Millipore, USA) with 8.0 um
pore polycarbonate filter inserted in 24-well plates.
HUVECs (4 × 105cells/well) in endothelial cell medium
without bovine serum were plated into the upper
chamber. The lower chamber was filled with 500 ul
endothelial cell medium containing 5 % bovine serum.
HDL with an apoA-I concentration of 100 μg/ml
were respectively co-cultured with HUVECs for 10 h.
Then all non-migrated cells in the upper chamber
were removed with a cotton swab. Migrated cells
were fixed and stained with 0.1 % (M/V) crystal vio-
let. Cells in each chamber were photographed with an
inverted microscope (Nikon, Japan). Cell migration
was quantified by counting the number of stained
cells per field in six random high-power (50X) fields.
Glycation analysis by mass spectrometry
HDL (30 ug protein per lane) was subjected to electro-
phoresis on 10 % SDS-polyacrylamide gels (SDS-PAGE).
The specific gel band (apoA-I) was excised and
destained with 25 mM NH4HCO3 in 50 % aceto-
nitrile. Proteins were reduced by 10 mM Dithiothrei-
tol and alkylated by 50 mM Iodoacetamide. After
being dried in 100 % acetonitrile, the gel band was
digested using sequencing grade trypsin (Promega) at
37 °C overnight. The extracted peptides were suspended
in 0.1 % formic acid and subjected to nanoLC-MS/MS
analysis. Peptides were eluted with a linear gradient from
5 to 40 % of 100 % acetonitrile and 0.1 % formic acid at a
flow rate of 300 nl/min using a 100 μm * 10 cm reversed-
phase C18 fused silica emitter made in house. The data-
dependent mass spectra were acquired with LTQ Orbitrap
Elite mass spectrometer (Thermo Fisher Scientific)
equipped with a nanoelectrospray ion source (Thermo
Fisher Scientific). Raw mass spectra files were processed
with Proteome Discoverer 1.4 (Thermo Fisher Scientific)
and searched in the human Uniprot database (version
2014_02) through the SEQUEST search engine. The pre-
cursor ion mass tolerance was set to 10 ppm, and MS/MS
tolerance 0.02 Da. Searching parameters were set as
follows: trypsin up to two missed cleavages, carbamido-
methyl cysteine as fixed modification, methionine oxida-
tion and glycation of lysine as variable modifications.
Electric injury model
Cell migration capacity in vivo was measured through
the electric injury model [25]. In general, mice were
anesthetized with 10 % (M/V) chloral hydrate at a dose
Table 1 Patient characteristics
Characteristic Healthy controls (n = 12) Patients with diabetes (n = 18) Patients with diabetic nephropathy (n = 18)
Age (years) 31.92 ± 2.11 57.78 ± 2.44*** 59.94 ± 1.67
Diabetes duration(years) 0 5.18 ± 1.77 11.83 ± 1.63#
Fasting glucose (mmol/l) 4.64 ± 0.09 11.28 ± 1.15*** 10.19 ± 1.24
Blood urea nitrogen (mmol/l) 4.55 ± 0.37 5.51 ± 0.41 8.15 ± 0.62##
HbA1C (%) 5.01 ± 0.12 10.04 ± 0.47*** 8.91 ± 0.61
Creatinine (umol/l) 57.78 ± 4.70 57.61 ± 2.26 112.40 ± 15.49##
eGFR (ml/min/1.73 m2) 131.30 ± 8.42 131.10 ± 11.01 70.18 ± 5.33###
Total cholesterol (mmol/l) 4.25 ± 0.17 4.71 ± 0.21 4.76 ± 0.41
Triglycerides (mmol/l) 1.04 ± 0.10 2.51 ± 0.32** 1.89 ± 0.30
HDL-C (mmol/l) 1.47 ± 0.07 1.01 ± 0.05*** 1.03 ± 0.08
LDL-C (mmol/l) 1.95 ± 0.10 2.90 ± 0.27** 3.02 ± 0.33
Data are expressed as mean ± SEM. HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol; **p<0.01, ***p<0.001, DM-HDL versus N-
HDL; ##p<0.01, ###p<0.001, DKD-HDL versus DM-HDL, one-way ANOVA
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of 3 ml/kg by intraperitoneal injection. Then the head
and the limbs were fixed after about 10 min. Neck skin
was sterilized with alcohol. Blunt dissect was performed
on the skin under a stereoscopic microscope (CNMI-
CRO, SMZ-B2), and then the left carotid artery was iso-
lated. A 4 mm plastic gasket was placed under the left
carotid artery in order to avoid damage to other tissues.
An electric current of 0.8 mA was applied for 2 s three
times. N-HDL, D-HDL, DN-HDL with an apoA-I con-
tent of 100 ug respectively were injected through the tail
vein every other day after carotid artery was injured. On
the first, third, and seventh day after carotid artery
injury, mice were anesthetized, and the injured vessel
segments were dissected and fixed in 4 % formalin for
8 h and then transferred into 20 %(M/V) sucrose
solutions overnight. Afterwards, vessel segments were
embedded under the optimal cutting temperature (ZLI-
9302, Zhongshan Goldenbridge Biotechnology Co., Ltd),
sharp-frozen in liquid nitrogen for 20 min, and stored
in -80 °C refrigerator for further use. Vessel segments
were cut into 7 um section with a freezing microtome
(Leica, Germany), and endothelial cell was stained
with hematoxylin–eosin, rabbit anti-CD31 antibody
(ZA-0568, Zhongshan Goldenbridge Biotechnology
Co., Ltd). Cell proliferation was detected with mouse
anti-PCNA (proliferating cell nuclear antigen) anti-
body (ZM-0213, Zhongshan Goldenbridge Biotechnol-
ogy Co., Ltd) for immunohistochemistry.
Western blot
The expression of PI3K and p-Akt were analyzed by
Western blot [21]. HUVECs were cultured in 6-well and
starved overnight until monolayers were formed. Cells
were then incubated with serum-deprived endothelial
cell medium respectively with PBS, N-HDL, D-HDL, or
DN-HDL with an apoA-I concentration of 100 μg/ml for
15 min. After the treatment, cells were harvested and
lysed with 100 ul RIPA (C1053, Beijing Applygen Tech-
nologies Inc.) containing 1 ul PMSF (P0100, Beijing
Solarbio Science & Technology Co., Ltd). Cell debris
was removed by centrifugation at 12,000 rpm for
20 min, and protein concentration was determined with
the Coomassie brilliant blue method. Cell lysates (60 ug
protein per lane) were subjected to electrophoresis on
10 % SDS-polyacrylamide gels (SDS-PAGE) and trans-
ferred onto nitrocellulose membranes (Pall Corporation,
USA) according to standard procedures. Then the mem-
branes were blocked for 2 h with 5 % non-fat milk.
Membranes were incubated with each primary antibody
(1:500–1:1000 dilution) overnight at 4 °C followed by
the appropriate horseradish peroxidase (HRP)-conju-
gated secondary antibody (1:1000 dilution). The expres-
sion was detected using the Super Signal West Pico Kit
(Pierce, USA) based on the manufacturer’s instructions.
Statistical analysis
The results of multiple observations are presented as the
means ± SEM. Data were analyzed with one-way
ANOVA or two-tailed Student’s t-test using GraphPad
Prism software (GraphPad Prism Software, USA). Any
difference with p < 0.05 was considered statistically sig-
nificant. ANOVA was used to detect the differences
among three or more groups. If p was smaller than 0.05,
a post-hoc test was used to determine the differences be-
tween groups for further analysis.
Results
Diabetic nephropathy high-density lipoprotein has a
decreased capacity to stimulate HUVECs migration
compared to diabetic high-density lipoprotein
HUVECs migration capacity was measured through
wound-healing migration assay and transwell migration
assay in vitro. In wound-healing assay, DN-HDL showed
a 17.12 % decrease compared with D-HDL (p < 0.05),
and 32.2 % decrease of D-HDL to N-HDL (p < 0.001,
Fig. 1a and b). To conform the effects on cells migration,
transwell assay was carried out and DN-HDL showed a
29.85 % decrease in comparison with D-HDL (p < 0.001).
D-HDL showed a 9.9 % decrease in comparison with N-
HDL (p < 0.01, Fig. 1c and d). Taken together, N-HDL
promoted the migration of EC, while D-HDL and DN-
HDL had a decreasing function, and the decrease was
severe in DN-HDL.
D-HDL and DN-HDL have impaired re-endothelialization
capacity in vivo
The re-endothelialization capacity of endothelial cells in
vivo was measured using an electric carotid injury model
[25]. Reendothelialization is the repopulation of the in-
tima impaired by endothelia cell migration from the in-
jury border [26]. Endothelial cells were delineated using
CD31 antibody and standard hematoxylin–eosin stain-
ing. Proliferating endothelial cells were identified by be-
ing stained with proliferating cell nuclear antigen
(PCNA) antibody [27] (Fig. 2a). On Day 1, migration
cells were barely observable. On Day 3, cell quantity
increased quickly when treated with N-HDL com-
pared with Day 1 (p < 0.001). Cells numbers on day 7
were higher than on Day 3 (p < 0.001). Cell migration
increased at the injury section in a time-dependent
manner. In comparison with D-HDL, DN-HDL
showed a 31.82 % decrease (p < 0.01) in cell migration
on Day 3 while N-HDL and D-HDL had no differ-
ence. On Day 7, DN-HDL showed an 18.87 % de-
crease compared with D-HDL (p < 0.01), and D-HDL
decreased 17.19 % in comparison with N-HDL (p < 0.01)
(Fig. 2b).
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Diabetic and diabetic nephropathy high density
lipoprotein have a high level glycation level through
HPLC/MS/MS
Advanced glycation end products (AGEs) are the nonen-
zymatic reaction of glucose and other reducing sugars
with amino groups of proteins. N-(Carboxymethyl)lysine
(CML) and N-(Carboxyethyl)lysine (CEL) are two major
nonenzymatic chemical modifications to proteins [28].
Except for CML and CEL, a new type of AGEs in which
lysine was modified with a molecule of glucose was
found in our experiment (Fig. 3a). An example MS/MS
spectrum is shown in Fig. 3b. This spectrum was derived
from the [M +H] + 2 form of the Ak162VQPYLDDFQK
peptide. Five glycated lysine residues in apoA-I were
monitored. DN-HDL showed a 2.55-fold-level increase
compared with D-HDL (DN-HDL 3.24e + 008 VS D-
HDL 1.27e + 008, p < 0.001), and D-HDL showed a 1.63-
fold-level increase compared with N-HDL (D-HDL
1.27e + 008 VS N-HDL 7.08e + 007, p < 0.01) (Fig. 3c).
Glycated apoA-I (G-apoA-I) and glycated HDL (G-HDL) have
a reduced capacity to stimulate endothelial cell migration
HDL is a complex mixture of lipoproteins associated
with many minor proteins and lipids which influence
HDL function [29, 30]. ApoA-I is the major component
in HDL, and many studies have found apoA-I can be
modified in a disease state damaging the apoA-I func-
tion [31, 32]. In order to find out whether HDL glyca-
tion causes HDL dysfunction and eliminate the impact
of other ingredients in HDL except for apoA-I, normal
HDL and apoA-I were incubated in 25 mM glucose so-
lution at 37 °C over 7 days. HDL glycation level was
confirmed using HPLC/MS/MS (Additional file 1: Figure
S1). Then glycated HDL (G-HDL) and glycated apoA-I
Fig. 1 Diabetic HDL and diabetic nephropathy HDL are less efficient in promoting HUVEC migration. a HUVEC monolayers were scratched by
manual scraping and treated with PBS(C), N-HDL (N), D-HDL (D), or DN-HDL (DN) respectively at 100 ug/ml apoA-I for 10 h. Migration into the
wound was photographed (50X objective lens). The red line indicated the scratch edge. b Distance between gaps was measured, and the results
were expressed as percentage of various HDL-treated cells in comparison with control. c HUVECs were treated with PBS(C), N-HDL (N), D-HDL (D),
or DN-HDL (DN) at 100 ug/ml apoA-I for 10 h respectively in transwell assay, and pictures were taken in six random high-power (50X) fields. d
Migratory cells were counted, and the results were expressed as percentage of various HDL-treated cells in comparison with control. Each experiment
was conducted in duplicate in three repeats and HDL were pooled from six individuals with different patients in each repeat. (n = 12 in control group,
n = 18 in diabetes group, and n = 18 in diabetic nephropathy group, **p < 0.01; ***p < 0.001; one-way ANOVA)
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(G-apoA-I) were used to measure the migration capacity
through wound-healing assay and transwell migration
assay. G-HDL showed a 39.58 % decrease compared
with N-HDL (G-HDL 87.25 ± 4.17 vs. N-HDL 144.40 ±
10.47, p < 0.001, Fig. 4a and b) in wound-healing assay.
G-HDL was less effective in EC migration compared
with N-HDL (G-HDL 84.78 ± 1.66 vs. N-HDL 118.90 ±
1.95, p < 0.001, 100 % of control, Fig. 4c and d) in
transwell migration assay. G-apoA-I showed a 30.58 %
decrease compared with N-apoA-I (G-apoA-I 97.19 ±
7.81 vs. N-apoA-I 140.00 ± 11.56, p < 0.05, Fig. 5a and b)
in wound-healing assay and 28.42 % decrease (G-apoA-I
177.30 ± 6.69 vs. N-apoA-I 247.70 ± 24.65, p < 0.05,
100 % of control, Fig. 5c) in transwell assay. Thus, the
function loss of D-HDL and DN-HDL in mediating cell
migration is consistent with the apoA-I glycation.
Fig. 2 D-HDL and DN-HDL have a reduced capability to promote reendothelialization in the electric injury model in vivo. a Frozen sections of
injured arteries on days 1, 3, and 7 treated with N-HDL, D-HDL and DN-HDL are stained with HE (hematoxylin–eosin), PCNA and CD31. Bar,
20 μm. b Quantitative analysis of cells in neointima was conducted using Prism (n = 4/group, **p < 0.01, D-HDL versus N-HDL; ##p < 0.01, DN-HDL
versus D-HDL; one-way ANOVA)
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D-HDL and DN-HDL reduce endothelial cell migration
involved in PI3K/Akt pathways
Cell migration involves the coordination of several
signal-transduction pathways, including PI3K expression
and Akt phosphorylation [7]. In order to illuminate the
mechanisms with which D-HDL and DN-HDL inhabited
cell migration, HUVECs were treated with PBS, N-HDL,
D-HDL or DN-HDL respectively at 100 ug/ml apoA-I
for 15 min. PI3K expression and Akt phosphorylation
level were analyzed using specific antibody by West-
ern blot. Compared with N-HDL, D-HDL and DN-
HDL reduced the capacity to activate PI3K and Akt
phosphorylation after 15 min of incubation with
HUVECs (Fig. 6).
Discussion
Clinical epidemiology has demonstrated that patients
with DN have a high cardiovascular risk, and CVD has
been identified as the primary cause of deaths in patients
with DN [33]. Dyslipidemia exacerbates the pathogenesis
of both CVD and DN [8]. Diabetic HDL is dysfunctional
in stimulating endothelial cell migration due to down
regulation of scavenger receptor B1 (SR-B1) expression
[21]. We used wound-healing and transwell migration
assays to assess the differences of HUVECs migration
promoted by N-HDL, D-HDL and DN-HDL respectively
showing that DN-HDL reduced the HUVECs migration
capacity much more than D-HDL did in vitro and in
vivo. A recent study indicates HDL lost its association
Fig. 3 Diabetic and diabetic nephropathic high-density lipoprotein have a high glycation level. a ApoA-I gel bands are digested and
analyzed by HPLC/MS/MS of N-HDL, D-HDL and DN-HDL samples. A: schematic diagram of lysine glycation with a molecule glucose.
b The CID spectra of AkVQPYLDDFQK specifically identify glucose modification that occurs on K96. c The peak areas for the modified
peptide in three groups. Results are presented with mean ± SEM in six separate experiments (n = 6/group, **p < 0.01,***p < 0.001,
one-way ANOVA)
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with lower mortality in patients with even minor impair-
ment of kidney function, whereas higher HDL levels al-
most turned into a potential cardiovascular risk factor in
patients with more advanced kidney failure [34]. This is
an important finding because DN is accompanied by an
increased triglyceride and decreased HDL levels and we
now know HDL disordered function in DN except its
low levels suggesting a possible explanation for why DN
has a higher risk of cardiovascular disease.
HDL is a complex mixture of lipoproteins associated
with many minor proteins and lipids that influence HDL
function [30]. ApoA-I constitutes 70 % of total HDL
protein, which exerts primary HDL anti-atherosclerotic
effects through RCT [32]. In order to eliminate the in-
fluence from such complexity, we used purified normal
apoA-I glycated in glucose, and we found that the gly-
cated apoA-I had a reduced capacity in endothelial cell
migration compared with normal apoA-I (Figs. 4 and 5).
As a result, glycated apoA-I in HDL accounts for the de-
creased migration capacity in HUVECs.
The formation and accumulation of advanced glyca-
tion end products (AGEs) are two of the most important
mechanisms involved in the pathophysiology of chronic
diabetic complications [35]. HDL is nonenzymatically
glycated at an increased level in diabetic individuals, but
little is known about the association between glycated
Fig. 4 Glycated HDL is less efficient in promoting HUVEC migration than normal HDL. a HUVEC monolayers were manually scratched and treated
with PBS(C), N-HDL (N), G-HDL (G) at the 100 ug/ml apoA-I for 10 h. Migration into the wound was photographed (50X objective lens). The red
line indicated the scratch edge. b Distance between gaps was measured, and the results were expressed as percentage of various HDL-treated
cells in comparison with control. c HUVECs were treated with PBS(C), N-HDL (N), or G-HDL (G) respectively at 100 ug/ml apoA-I for 10 h
in transwell assay. d Migratory cells were counted, and the results were expressed as percentages of various HDL -treated cells in comparison with
control (**p < 0.01; ***p < 0.001; one-way ANOVA)
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HDL and endothelium dysfunction in diabetes [36].
We used mass spectrometry to analyze the level of gly-
cated apoA-I, and the level could represent HDL gly-
cation in vivo. We found HDL glycation levels were
more salient in DN than in diabetes without complica-
tions (Fig. 3). The higher HDL glycation level, the fur-
ther capacity to stimulate endothelial cell migration
was reduced. A previous study indicated that apoA-I
glycation level is affected by glucose concentration in
vitro [16], and with a decrease in renal function, the
clearance capacity of AGEs is diminished [37]. In this
study, patients with DN had similar age and glucose
levels but lower eGFR(estimated glomerular filtration
rate) compared with those without nephropathy. These
differences may contribute to the high level of glycated
HDL in DN.
Oxidized HDL diminishes HUVEC migration through
the PI3K/Akt and MEK/ERK pathways [38], and HDL
activates cyclin D1 via phosphatidylinositol 3-kinase
(PI3K)/Akt stimulation in the healing process by pro-
moting EPC proliferation, migration and ‘tube’ formation
[39]. To examine the mechanism in which DN-HDL and
D-HDL reduce HUVECs migration in this study, we an-
alyzed the expression of PI3K and p-Akt and found that
N-HDL induced PI3K expression and Akt phosphoryl-
ation while D-HDL and DN-HDL had less capacity to
activate these phosphorylations. In fact, the capacity re-
duction turned more severe in DN-HDL (Fig. 6).
The study used mass spectrometry to measure the
level of HDL glycation both in diabetes without compli-
cations and DN and found that apoA-I glycation levels
are higher in DN-HDL than in D-HDL, and that DN-
HDL severely diminished cell migration capacity. It has
been demonstrated that endothelial cell migration is the
major mechanism of initial adjacent surface coverage in
vitro [40]. Accordingly, delayed re-endothelialization due
to inhibition of migration may contribute significantly to
the formation of irreversible vascular disease [40]. HDL’s
capacity to promote cell migration is one of the mecha-
nisms for protecting vascular vessels from damages. Our
findings suggest that glycation impairs HDL function,
and dysfunctional HDL may lead to the reduction of the
Fig. 5 Glycated apoA-I is less efficient in promoting HUVEC migration compared with normal apoA-I. a HUVEC monolayers were manually
scratched and treated with PBS(C), N-apoA-I (N), G-apoA-I (G) at the 100 ug/ml apoA-I for 10 h. Migration into the wound was photographed
(50X objective lens). The red line indicated the scratch edge. b Distance between gaps was measured, and the results were expressed as
percentages of various apoA-I-treated cells in comparison with control. c HUVECs were treated with PBS(C), N-apoA-I (N), or G-apoA-I (G)
respectively at 100 ug/ml apoA-I for 10 h in transwell assay. Migratory cells were counted, and the results were expressed as percentages of
various apoA-I -treated cells in comparison with control (*p < 0.05;**p < 0.01; ***p < 0.001; one-way ANOVA)
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re-endothelialization capability and potentially explains
why there is excessive CVD in DN patients.
Conclusions
This study investigated HDL function in diabetic ne-
phropathy and found that, compared with D-HDL, DN-
HDL more significantly reduced the capacity to stimu-
late cell migration in vitro and in vivo due to a higher
glycation level. These findings indicate one of the poten-
tial mechanisms that explain why diabetic nephropathy
has a higher risk of cardiovascular disease. More atten-
tion should be paid to the level of HDL glycation and its
function on CVD in diabetic nephropathy.
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(50X objective lens). Distance between gaps was measured, and the re-
sults were expressed as percentage of various HDL-treated cells in com-
parison with control. C: HUVECs were treated with PBS, N-HDL, D-HDL,
DN-HDL or G-HDL at 100 ug/ml apoA-I for 10 hours respectively in trans-
well assay, and pictures were taken in 6 random high-power (50X) fields.
Migratory cells were counted, and the results were expressed as percent-
age of various HDL-treated cells in comparison with control (*p<0.05;
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